Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective "Lymphomes Malins B" protocols. A Société Française des Cancers de l'Enfant study

Haematologica
Anne JourdainSFCE LNH Committee

Abstract

To describe relapsed B-cell lymphoma or leukemia in children/adolescents treated with a "Lymphomes Malins B" regimen and their outcome and to identify prognostic factors for survival, we studied relapses in the LMB89, 96 and 2001 studies of the Société Française d'Oncologie Pédiatrique (Société Française des Cancers de l'Enfant). Therapeutic guidelines at relapse were to obtain a second complete remission and to consolidate the remission with high-dose chemotherapy followed by autologous stem-cell transplantation. Between July 1989 and March 2007, 67 patients of 1322 (5%) relapsed: 57 had Burkitt lymphoma and 10 had large-cell histology. Three patients were initially treated in risk group A, 41 in group B and 23 in group C. Thirty-three patients had a relapse in one site (15 in the central nervous system) and 34 at multiple sites. Sixty-five patients received salvage chemotherapy and 33 achieved complete remission. Forty-one patients also received high-dose chemotherapy followed by autologous (n=33) or allogeneic (n=8) transplantation. With a median follow-up of 6.4 years, the 5-year survival rate was 29.9%. Nineteen patients were still alive, all but one (group A) received consolidation treatment. Multivariate analysis showed ...Continue Reading

Citations

Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Véronique Minard-ColinCatherine Patte
Aug 29, 2018·Hematology·Felix Gaytan-MoralesUNKNOWN Mexican Association of Pediatric Oncology and Hematology (AMOHP)
Jun 13, 2019·European Journal of Nuclear Medicine and Molecular Imaging·Suyun ChenHui Wang
Mar 7, 2020·British Journal of Haematology·Maria L MoletiRobin Foà
Aug 7, 2020·Journal of the National Comprehensive Cancer Network : JNCCN·Aliza Gardenswartz, Mitchell S Cairo
Jul 10, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew J EhrhardtDaniel A Mulrooney
Mar 16, 2017·American Journal of Hematology·Nicholas J ShortElias Jabbour
Nov 28, 2018·The Cancer Journal·Jessica Hochberg, Mitchell S Cairo
Aug 7, 2020·Journal of the National Comprehensive Cancer Network : JNCCN·Kimberly DaviesDeborah A Freedman-Cass
Apr 2, 2021·CA: a Cancer Journal for Clinicians·Erin ButlerTheodore W Laetsch

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.